MiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H Selection for Deployable Cell Therapies
Key Highlights
- ➤$0.2 million agenT-797 revenue marks MiNK’s first pre-commercial product revenue
- ➤Phase 2 ARDS trial enrolling; U.S. dosing expected before year-end, data due 2H2027
- ➤ARPA-H selected agenT-797 for BoSS deployability program with up to $87 million funding
- ➤$7.5 million cash at September 30, down from $8.8 million at June 30
- ➤Net loss per share fell 23% year over year to $0.50
Expert Statements
Jennifer Buell, President and Chief Executive Officer of MiNK Therapeutics
“We now have a randomized trial running in critical illness, multiple clinical programs enrolling and a path toward pivotal development. This quarter, physicians outside our trials began requesting agenT-797 for their patients, bringing our first pre-commercial revenue”
Jennifer Buell, President and Chief Executive Officer of MiNK Therapeutics
“The same unmodified iNKT cells, from the same donor, that drove a 77% disease control rate in PD-1-refractory gastroesophageal cancer are now in a placebo-controlled trial in ARDS, where nearly four in ten patients die and no effective approved drug changes that outcome. Our focus now is delivering the randomized readout designed to show what these cells can do for these patients.”
Terese Hammond, Head of Inflammatory and Pulmonary Diseases at MiNK Therapeutics
“I treat ARDS in the ICU, and it is the condition I see most often and can do the least about. We keep patients alive and wait for the immune system to right itself, and too often it does not”
Terese Hammond, Head of Inflammatory and Pulmonary Diseases at MiNK Therapeutics
“Because agenT-797 comes from inventory, with no matching or conditioning, it can be given in the window when it matters, in any ICU that can thaw and infuse it. That is why we are running the randomized trial.”
* Patients with serious unmet medical need access agenT-797 through physician-requested named-patient access; generating the Company’s first product revenue * Selected as the cell therapy for the Draper-led team in ARPA-H’s BoSS program (up to $87 million in program wide funding) to move living medicines toward room temperature deployability * Randomized Phase 2 ARDS trial of agenT-797 plus standard of care (SOC) enrolling with U.S. dosing expected before year-end in patients with ~40% 28-day mortality, no effective approved therapies (estimated 93,000 U.S. patients annually) * Data presented at SITC 2026: agenT-797 and MiNK-215 acted as “living senolytics,” clearing senescent cells chemotherapy leaves behind – cells that fuel treatment resistance and fibrotic lung disease; agenT-797 also unlocked tumor-cell killing with BOT/BAL in LM MSS CRC organoids * Disciplined execution: 23% year-over-year improvement in net loss per share, 44% G&A efficiency gain and the most capital-efficient quarter of 2026 NEW YORK, Nov. 11, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering unmodified, off-the-shelf allogeneic invariant natural killer T (iNKT) cell therapies, reported financial results for the third quarter ended September 30, 2026, and highlighted a quarter in which agenT-797 realized pre-commercial revenue, its randomized trial in acute respiratory distress syndrome (ARDS) is advancing , and an ARPA-H program selected the Company’s cells to generate living medicines can be delivered without a freezer. Full financial results will be reported on Thursday, November 12, 2026.
Get started
Create a free account to read the full story.